NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

DIMERIX LIMITED (DXB)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
DIMERIX LIMITED01/12/2015
SUN BIOMEDICAL LIMITED19/12/200701/12/2015
HARRINGTON GROUP LIMITED09/05/199719/12/2007
AUSFOR LIMITED09/05/1997

Shareholder links

Our website ranking of DXB: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Group
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000DXB7
Address: 425 Smith Street Fitzroy VIC 3065 Australia
Tel:  1300 813 321Fax: +61 8 9321 1204

Date first listed: 04/02/1993
Company Secretary: Hamish George
Sector: Pharmaceuticals Biotechnology & Life Sciences Industry Group: XHJ
Activities: A Clinical stage (Phase II) biotechnology business commercialising new therapies for under-served and unmet medical needs globally

News & Events

Expand this box to read and print

The suspension of trading in the securities of Dimerix Limited ("˜DXB') will be lifted immediately following the release by DXB of an announcement regarding a capital raising.

04/05/2023

The company releases an Investor Presentation.

04/05/2023

The company releases a notice of proposed issue of securities.

04/05/2023

Dimerix is seeking to raise $12 million, through a combination of an entitlement offer and convertible notes, with an option for up to a further $8.5 million in convertible notes. The entitlement offer seeks to raise up to approximately $8.56 million through a partially underwritten non-renounceable entitlement offer to shareholders of 1 New Share for every 3 Shares held by eligible shareholders on the Record Date at an issue price of $0.08 per New Share. Approximately $4.06 million of the entitlement offer is underwritten. Every two shares under the Entitlement Offer will be accompanied by two free-attaching options in total. Commitment for full entitlement uptake and sub-underwriting of a portion of shortfall from substantial shareholder Mr Peter Meurs and directors Dr Nina Webster and Dr Sonia Poli. Firm sub-underwriting commitments from international institutional and sophisticated investors. Funds raised to continue the Company's Phase 3 FSGS clinical program past 1st interim data, including clinical, manufacturing and partnering activities. Dimerix has entered into a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC, a US-based investment fund to access up to $12 million of funding, with an initial tranche of $3.5 million ($1.9 million of which is subject to shareholder approval) and a further optional tranche of up to $8.5 million by mutual agreement.

04/05/2023

The securities of Dimerix Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DXB, pending the release of an announcement regarding a capital raise.

03/05/2023

The suspension of trading in the securities of Dimerix Limited will be lifted immediately, following receipt of an announcement regarding the proposed capital raising undertaken by the Company.

06/12/2017

The company releases a notice to shareholders regarding the non-renounceable entitlement offer. Dimerix is pleased to confirm it has received firm commitments to participate in the Entitlement Offer from major shareholders, Directors and management to the amount of at least $800,000.

06/12/2017

An entitlement offer booklet was also released by the company.

06/12/2017

The company releases an entitlement offer cleansing notice in relation to the 1 for 2 offer.

06/12/2017

The company intends to undertake a 1 for 2 pro rata non-renounceable entitlement offer of fully paid ordinary shares in Dimerix to raise approximately $5,524,906. The offer price for the Entitlement Offer will be 12 cents per New Share. The Entitlement Offer Price represents a 31% discount to the 15 day VWAP to 30 November 2017 of Dimerix shares.

06/12/2017

The securities of Dimerix Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement.

05/12/2017

we understand that on or about this date the company consolidated its shares 1 for 20

31/10/2017

we understand that on or about this date the company consolidated its shares 1 for 20

31/10/2017

name changed from Sun Biomedical Limited

01/12/2015

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    27/03/2024Nina Webster33,000$0.310$10,230
    07/09/2018Nina Webster45,000$0.110$4,950
    25/05/2018David Franklyn200,000$0.100$20,000
    24/05/2018James Williams50,000$0.100$5,000
    28/02/2017Sonia Poli2,600,000$0.008$20,800

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Mark DiamondChairman01/12/2023
    Sonia PoliManaging Director05/07/2015
    Nina WebsterManaging Director, CEO27/08/2018
    Hamish GeorgeCFO06/05/2019
    Clinton SnowNon Exec Director01/05/2023
    Hugh AlsopNon Exec Director01/05/2017

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    James WilliamsNon Exec Chairman26/11/201523/12/2022
    David FranklynNon Exec Director24/11/201511/10/2019
    Kathy HarrisonCOO07/11/201630/11/2018
    Liz JazwinskaNon Exec Director17/12/201503/11/2016
    Howard DigbyExecutive Chairman22/01/201324/11/2015
    Anton UvarovExecutive Director20/11/201324/11/2015
    Evan CrossNon Exec Director01/03/201205/07/2015
    Peter WebseNon Exec Director22/01/201303/07/2015
    Terry CuthbertsonNon Exec Director02/09/200919/09/2013
    Peter HerdIndependent Director01/10/200922/01/2013
    Gary StewartNon Exec Director29/01/201022/01/2013
    Peter KingExecutive Chairman24/02/200530/10/2010
    Jim Hallam24/10/200703/10/2009
    Andrew PaiceCFO05/06/200604/09/2009
    Brian AndrewsManaging Director05/06/200624/02/2008
    Peter BartleetNon Exec Director26/02/200422/06/2007
    Peter BoonenExecutive Director30/08/200522/06/2007
    Taylor FogelquistCOO04/02/200507/06/2006
    Chris NicholsNon Exec Director04/02/200507/06/2006
    Michael SilverNon Exec Director11/07/200114/12/2005
    Franco CanturiNon Exec Director29/09/200313/02/2005
    Anthony SilverNon Exec Director13/02/2005
    Lindsay SanfordNon Exec Director22/01/200301/10/2003
    William TienNon Exec Director14/02/200319/07/2003
    Gary A. WilliamsNon Exec Director13/06/200208/03/2003
    Michael IvkovicManaging Director31/01/200124/01/2003
    David H. BrookNon Exec Director09/11/199213/07/2001

    Date of first appointment, title may have changed.